Buscar
Mostrando ítems 1-2 de 2
Artículo
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/ Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis
(AMER ASSOC CANCER RESEARCH, 2022)
Purpose: New therapeutic options are needed in relapsed/refrac tory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide based schedules can reverse rituximab refractoriness in lymphoma. Patients and Methods: In the ...
Artículo
The complexity of cancer immunotherapy illustrated through skin tumors
(Wichtig Editore, 2022)
Skin tumours are among the cancer types most sensitive to immunotherapy, due to their unique immunogenic features including skin-associated lymphoid tissue, high mutational load, overexpression of tumour antigens, and ...